<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303105</url>
  </required_header>
  <id_info>
    <org_study_id>406-102-00003</org_study_id>
    <secondary_id>JapicCTI-173726</secondary_id>
    <nct_id>NCT03303105</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine</brief_title>
  <official_title>A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of
      TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at
      675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine
      patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Day562</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the number of migraine days</measure>
    <time_frame>Day337</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average of migraine days</measure>
    <time_frame>Day337</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the number of headache days of any severity</measure>
    <time_frame>Day337</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average of headache days of any severity</measure>
    <time_frame>Day337</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>TEV-48125 (225 mg/1 month) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses to subjects of 225 mg/1 month group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 (675 mg/3 month) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses to subjects of 675 mg/3 months group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125</intervention_name>
    <description>TEV-48125 will be administered subcutaneously once every 4 weeks or 12 weeks.</description>
    <arm_group_label>TEV-48125 (225 mg/1 month) group</arm_group_label>
    <arm_group_label>TEV-48125 (675 mg/3 month) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with migraine onset at ≤50 years of age

          -  Patient signs and dates the informed consent document.

          -  Patient has history of migraine or clinical judgment suggests a migraine diagnosis

          -  Patient fulfills the criteria for episodic migraine (EM) or chronic migraine (CM)

          -  All patients must be of nonchildbearing potential

             ･ Patients must simultaneously use 2 forms of highly effective contraception methods

               -  Patients will remain abstinent throughout the study

               -  Patients have sexual preference that precludes the possibility of pregnancy.

          -  Female patients of childbearing potential must have a negative serum beta-human
             chorionic gonadotropin (β-HCG) pregnancy test prior to randomization (confirmed by
             urine dipstick at baseline).

          -  The patient must be willing and able to comply with study restrictions, to remain at
             the clinic for the required duration during the study period, and to return to the
             clinic for the follow-up evaluation as specified in this protocol.

        Exclusion Criteria:

          -  Clinically significant findings at the discretion of the investigator

          -  Evidence or medical history of clinically significant psychiatric issues, including
             any suicide attempt in the past, or suicidal ideation with a specific plan in the past
             2 years

          -  History of clinically significant cardiovascular disease or vascular ischemia

          -  Known infection or history of human immunodeficiency virus, tuberculosis, or chronic
             hepatitis B or C infection

          -  Past or current history of cancer in the past 5 years, except for appropriately
             treated nonmelanoma skin carcinoma

          -  Pregnant or nursing females

          -  History of hypersensitivity reactions to injected proteins, including monoclonal
             antibodies.

          -  Participation in a clinical study of a new chemical entity or a prescription medicine
             within 2 months before study drug administration or 5 half-lives, whichever is longer

          -  Any finding considered clinically significant in the judgment of the investigator

          -  History of alcohol or drug abuse during the past 2 years, or alcohol or drug
             dependence during the past 5 years

          -  The patient cannot participate or successfully complete the study, in the opinion of
             their healthcare provider or the investigator, for any of the following reasons:

             ･ mentally or legally incapacitated or unable to give consent for any reason

               -  in custody due to an administrative or a legal decision, under tutelage, or being
                  admitted to a sanitarium or social institution

               -  unable to be contacted in case of emergency

               -  has any other condition, which, in the opinion of the investigator, makes the
                  patient inappropriate for inclusion in the study

          -  Patient is a study center or sponsor employee who is directly involved in the study or
             the relative of such an employee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Knanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

